Novo Nordisk’s ocedurenone Phase III flop costs company $816m
The trial was estimated to enrol approximately 600 patients from 150 sites in the US, Europe, and Asia, with the first patient dosed at the end of 2021.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
